
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4815966/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Photochemically-Mediated Inflammation and Cross-Presentation of Mycobacterium bovis BCG Proteins Stimulates Strong CD4 and CD8 T-Cell Responses in Mice. Frontiers in Immunology, 2022, 13, 815609.	2.2	3
2	Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans. Frontiers in Allergy, 2022, 3, 832010.	1.2	5
3	Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen. Clinical and Experimental Allergy, 2022, 52, 747-759.	1.4	13
4	Kinetics and persistence of antiâ€SARSâ€CoVâ€2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort. Immunity, Inflammation and Disease, 2022, 10, .	1.3	5
5	Amphiphilic Cyclodextrinâ€Based Nanoparticulate Vaccines Can Trigger Tâ€Cell Immune Responses. Advanced NanoBiomed Research, 2022, 2, .	1.7	4
6	Photochemical internalization (PCI)-mediated activation of CD8 T cells involves antigen uptake and CCR7-mediated transport by migratory dendritic cells to draining lymph nodes. Journal of Controlled Release, 2021, 332, 96-108.	4.8	10
7	Cell-Specific Delivery Using an Engineered Protein Nanocage. ACS Chemical Biology, 2021, 16, 838-843.	1.6	16
8	A Comparative Study of Real-Time RT-PCR–Based SARS-CoV-2 Detection Methods and Its Application to Human-Derived and Surface Swabbed Material. Journal of Molecular Diagnostics, 2021, 23, 796-804.	1.2	24
9	A tissue culture infectious dose-derived protocol for testing of SARS-CoV-2 neutralization of serum antibodies on adherent cells. STAR Protocols, 2021, 2, 100824.	0.5	3
10	Editorial: Frontiers' Research Topic "Cancer Vaccines: Time to Think Differently!― Frontiers in Immunology, 2021, 12, 771319.	2.2	0
11	Functional differences between protamine preparations for the transfection of mRNA. Drug Delivery, 2020, 27, 1231-1235.	2.5	26
12	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. Cancers, 2020, 12, 1694.	1.7	13
13	Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines. Cancers, 2020, 12, 165.	1.7	29
14	A dual role for hepatocyte-intrinsic canonical NF-κB signalingÂinÂvirus control. Journal of Hepatology, 2020, 72, 960-975.	1.8	18
15	FBXO25 Promotes Cutaneous Squamous Cell Carcinoma Growth and Metastasis through Cyclin D1. Journal of Investigative Dermatology, 2020, 140, 2496-2504.	0.3	11
16	Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help. Frontiers in Immunology, 2019, 10, 1548.	2.2	8
17	BATF3-dependent dendritic cells drive both effector and regulatory T-cell responses in bacterially infected tissues. PLoS Pathogens, 2019, 15, e1007866.	2.1	38
18	Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice. European Journal of Pharmaceutical Sciences, 2018, 115, 362-368.	1.9	3

#	Article	IF	CITATIONS
19	Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling. Journal of Immunology, 2018, 200, 3151-3159.	0.4	39
20	Distinct T helper cell dependence of memory Bâ€cell proliferation versus plasma cell differentiation. Immunology, 2017, 150, 329-342.	2.0	20
21	TLR4 as a negative regulator of keratinocyte proliferation. PLoS ONE, 2017, 12, e0185668.	1.1	17
22	IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant <scp>MAT</scp> â€Feld1 in human. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1366-1370.	2.7	25
23	Dosing intervals in intralymphatic immunotherapy. Clinical and Experimental Allergy, 2016, 46, 504-507.	1.4	5
24	Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes. Molecular Pharmaceutics, 2016, 13, 320-329.	2.3	25
25	Abstract A008: Photochemical internalization: Light-induced enhancement of MHC Class I antigen presentation, giving strong enhancement of cytotoxic T-cell responses to vaccination. Cancer Immunology Research, 2016, 4, A008-A008.	1.6	1
26	Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 707-710.	2.7	76
27	A bizarre attack on the freedom of scientific expression. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1037-1038.	2.7	0
28	Photosensitizer and Light Pave the Way for Cytosolic Targeting and Generation of Cytosolic CD8 T Cells Using PLGA Vaccine Particles. Journal of Immunology, 2015, 195, 166-173.	0.4	22
29	Parenteral Vaccine Administration: Tried and True. Advances in Delivery Science and Technology, 2015, , 261-286.	0.4	4
30	Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis. Vaccine, 2015, 33, 1353-1359.	1.7	45
31	Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells. Journal of Controlled Release, 2015, 198, 10-17.	4.8	35
32	Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 134, 965-967.e4.	1.5	40
33	Multivalent paediatric allergy vaccines protect against allergic anaphylaxis in mice. Clinical and Experimental Allergy, 2014, 44, 429-437.	1.4	2
34	Intralymphatic Immunotherapy and Vaccination in Mice. Journal of Visualized Experiments, 2014, , e51031.	0.2	12
35	Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen. Journal of Controlled Release, 2014, 174, 143-150.	4.8	34
36	Semi-permeable coatings fabricated from comb-polymers efficiently protect proteins in vivo. Nature Communications, 2014, 5, 5526.	5.8	61

#	Article	IF	CITATIONS
37	Intralymphatic immunotherapy: Time interval between injections is essential. Journal of Allergy and Clinical Immunology, 2014, 133, 930-931.	1.5	40
38	Preclinical efficacy and safety of an anti-IL-1Î ² vaccine for the treatment of type 2 diabetes. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14048.	1.8	47
39	A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials. Rhinology, 2014, 52, 137-141.	0.7	2
40	Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine, 2013, 31, 1057-1064.	1.7	19
41	Risk Assessment of Hymenoptera Re-Sting Frequency: Implications for Decision-Making in Venom Immunotherapy. International Archives of Allergy and Immunology, 2013, 160, 86-92.	0.9	20
42	The antihistamines clemastine and desloratadine inhibit <scp>STAT</scp> 3 and câ€Myc activities and induce apoptosis in cutaneous Tâ€cell lymphoma cell lines. Experimental Dermatology, 2013, 22, 119-124.	1.4	16
43	Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 34-41.	2.0	20
44	TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell–independent isotype switch in mice. Blood, 2013, 121, 85-94.	0.6	39
45	New routes for allergen immunotherapy. Human Vaccines and Immunotherapeutics, 2012, 8, 1525-1533.	1.4	29
46	Encapsulation of antigen in poly(d,l-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 274-281.	2.0	19
47	Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: AÂdouble-blind, placebo-controlled dose escalation study. Journal of Allergy and Clinical Immunology, 2012, 129, 128-135.	1.5	148
48	Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. Journal of Allergy and Clinical Immunology, 2012, 129, 1290-1296.	1.5	236
49	The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 638-646.	2.7	14
50	Clemastine causes immune suppression through inhibition of extracellular signal-regulated kinase–dependent proinflammatory cytokines. Journal of Allergy and Clinical Immunology, 2011, 128, 1286-1294.	1.5	17
51	Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine, 2011, 29, 1339-1346.	1.7	53
52	Intralymphatic Immunotherapy: From the Rationale to Human Applications. Current Topics in Microbiology and Immunology, 2011, 352, 71-84.	0.7	31
53	Inflammasome activation and IL- $\hat{1}^2$ target IL- $\hat{1}^\pm$ for secretion as opposed to surface expression. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18055-18060.	3.3	166
54	Relief from Zmp1-Mediated Arrest of Phagosome Maturation Is Associated with Facilitated Presentation and Enhanced Immunogenicity of Mycobacterial Antigens. Vaccine Journal, 2011, 18, 907-913.	3.2	54

#	Article	IF	CITATIONS
55	Lympho-geographical concepts in vaccine delivery. Journal of Controlled Release, 2010, 148, 56-62.	4.8	61
56	Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. Journal of Controlled Release, 2010, 147, 342-349.	4.8	194
57	Histamine H1 Receptor Promotes Atherosclerotic Lesion Formation by Increasing Vascular Permeability for Low-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 923-930.	1.1	67
58	Nickel sensitisation in mice: A critical appraisal. Journal of Dermatological Science, 2010, 58, 186-192.	1.0	5
59	Intralymphatic Injections as a New Administration Route for Allergen-Specific Immunotherapy. International Archives of Allergy and Immunology, 2009, 150, 59-65.	0.9	98
60	Use of Aâ€ŧype CpG oligodeoxynucleotides as an adjuvant in allergenâ€specific immunotherapy in humans: a phase I/IIa clinical trial. Clinical and Experimental Allergy, 2009, 39, 562-570.	1.4	194
61	Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 172-178.	2.7	44
62	Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology, 2009, 124, 997-1002.	1.5	180
63	Intralymphatic immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 537-543.	1.1	75
64	Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood, 2009, 113, 377-388.	0.6	126
65	Medication with antihistamines impairs allergenâ€specific immunotherapy in mice. Clinical and Experimental Allergy, 2008, 38, 512-519.	1.4	19
66	Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. Journal of Controlled Release, 2008, 130, 161-167.	4.8	57
67	Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17908-17912.	3.3	308
68	Antigen kinetics determines immune reactivity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5189-5194.	3.3	158
69	A Virus-Like Particle-Based Vaccine Selectively Targeting Soluble TNF-α Protects from Arthritis without Inducing Reactivation of Latent Tuberculosis. Journal of Immunology, 2007, 178, 7450-7457.	0.4	104
70	Analysis of the Relationship between Pollinosis and Date of Birth in Switzerland. International Archives of Allergy and Immunology, 2007, 143, 269-275.	0.9	22
71	Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Review of Vaccines, 2007, 6, 471-474.	2.0	43
72	Evaluation of visual analog scales for the assessment of symptom severity in allergic rhinoconjunctivitis. Annals of Allergy, Asthma and Immunology, 2007, 98, 134-138.	0.5	11

#	Article	IF	CITATIONS
73	A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles. Pharmaceutical Research, 2007, 24, 1927-1935.	1.7	61
74	Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine, 2006, 24, 1389-1394.	1.7	16
75	Coated Textiles in the Treatment of Atopic Dermatitis. , 2006, 33, 144-151.		49
76	Antimicrobial Silk Clothing in the Treatment of Atopic Dermatitis Proves Comparable to Topical Corticosteroid Treatment. Dermatology, 2006, 213, 228-233.	0.9	49
77	Immunotherapeutic Targeting of Allergic Disease. Inflammation and Allergy: Drug Targets, 2006, 5, 243-252.	1.8	9
78	A Cutaneous Allergen Neutralisation Test That Correlates with the Duration of Venom Immunotherapy. International Archives of Allergy and Immunology, 2006, 141, 377-383.	0.9	5
79	Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Advanced Drug Delivery Reviews, 2005, 57, 357-376.	6.6	299
80	Immunity in response to particulate antigen-delivery systems. Advanced Drug Delivery Reviews, 2005, 57, 333-355.	6.6	277
81	Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clinical and Experimental Allergy, 2005, 35, 1591-1598.	1.4	57
82	Direct intralymphatic injection of peptide vaccines enhances immunogenicity. European Journal of Immunology, 2005, 35, 568-574.	1.6	105
83	Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. European Journal of Immunology, 2005, 35, 1869-1876.	1.6	70
84	Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. European Journal of Immunology, 2005, 35, 3591-3598.	1.6	46
85	Efficacy and Safety of Allergen-Specific Immunotherapy in Rhinitis, Rhinoconjunctivitis, and Bee/Wasp Venom Allergies. International Reviews of Immunology, 2005, 24, 519-531.	1.5	13
86	Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. Journal of Controlled Release, 2004, 99, 345-355.	4.8	23
87	CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells. European Journal of Immunology, 2004, 34, 91-97.	1.6	29
88	An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. Journal of Pharmaceutical Sciences, 2003, 92, 957-966.	1.6	31
89	Anti-mycobacterial immunity induced by a single injection of M. leprae Hsp65-encoding plasmid DNA in biodegradable microparticles. Immunology Letters, 2003, 90, 81-85.	1.1	26
90	On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharmaceutical Research, 2002, 19, 1330-1336.	1.7	37

#	Article	IF	CITATIONS
91	Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends in Biotechnology, 2000, 18, 203-211.	4.9	37
92	Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine, 2000, 19, 1047-1054.	1.7	54
93	Technological considerations related to the up-scaling of protein microencapsulation by spray-drying. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50, 413-417.	2.0	62
94	Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50, 129-146.	2.0	207
95	Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs. European Journal of Pharmaceutics and Biopharmaceutics, 1999, 47, 193-201.	2.0	39
96	Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine, 1999, 18, 209-215.	1.7	62
97	Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents. Pharmaceutical Research, 1998, 15, 1111-1116.	1.7	48
98	Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharmaceutical Research, 1998, 15, 1103-1110.	1.7	141
99	Release of tetanus toxoid from adjuvants and PLGA microspheres: How experimental set-up and surface adsorption fool the pattern. Journal of Controlled Release, 1998, 56, 209-217.	4.8	29
100	Physico-chemical and antigenic properties of tetanus and diphtheria toxoids and steps towards improved stability. Biochimica Et Biophysica Acta - General Subjects, 1998, 1425, 425-436.	1.1	33
101	Thermodynamic approach to protein microencapsulation into poly(D,L-lactide) by spray drying. International Journal of Pharmaceutics, 1996, 129, 51-61.	2.6	63
102	Safety and Satisfaction in High-Definition Power-Assisted Liposculpture in Men Under Local Anesthesia. The American Journal of Cosmetic Surgery, 0, , 074880682110247.	0.1	0